Day One Biopharmaceuticals Inc

DAWN

$16.52

Closing

▲4.62%

1D

▲13.15%

YTD

Market cap

$1.44B

52 week high

$17.83

52 week low

$9.68

Volume

267,918

Check if the stock is halal

Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.

Get started from just $3.99/month

Market cap

$1.44B

Analysts' Rating

BUY

Price Target (Mean)

37.77778

Total Analysts

10

P/E

Operating Margin

0.00%

Beta

Revenue Growth (Annual)

0.00%

52 week high

$17.83

52 week low

$9.68

Div. Yield

%

EPS Annual Growth

-11.48

Note on Purification and Zakat

  • Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly). 
  • If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
  • For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them. 

Company Profile

Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing targeted therapies for patients of all ages with life threatening diseases. The Company seeks to identify, acquire and develop product candidates that target high-value oncogenic drivers in cancers with unmet needs, with an initial focus on pediatric patients. Its lead product candidate, tovorafenib (DAY101), is an oral, brain-penetrant, highly selective type II pan-rapidly accelerated fibrosarcoma (pan-RAF), kinase inhibitor. Its second product candidate, pimasertib, is an oral, highly selective small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), a well-characterized key signaling node in the MAPK pathway. It has initiated an open-label, multicenter, Phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib monotherapy or combination therapy, which consists of two substudies, such as Substudy 1 and Substudy 2.